Entelos Inc.



Entelos, Inc. (LSE: ENTL), a leading life sciences company using next-generation
predictive technologies for drug discovery and development, is pleased to
announce today that Pfizer Ireland Pharmaceuticals (formerly Pfizer Overseas
Pharmaceuticals), a subsidiary of Pfizer Inc., ("Pfizer") and one of the
Company's current shareholders, has entered into an agreement to subscribe for
2,516,299 Entelos common shares at 29.1 pence per share.

Transaction details

Pfizer Ireland Pharmaceuticals has agreed to invest $1.5 million in cash to
acquire 2,516,299 new Entelos shares representing 3.3% of the enlarged share
capital of Entelos. The subscription price of 29.1 pence per share is calculated
from the average closing price of the 10 trading days prior to and including 25
October 2007, and represents a premium of approximately 23% to the closing share
price of 22.5 pence on 30 October 2007, the last practicable date prior to this
announcement. Following the subscription, Pfizer Ireland Pharmaceuticals will
hold a total of 5,214,334 Entelos shares representing 6.9% of the enlarged share
capital of Entelos.

The funds raised in this subscription will be used as additional working capital
as the Company pursues its growth strategy of building and acquiring
complementary predictive technologies to generate revenue from services and
technology licensing.

All of the shares to be issued will be subject to an orderly marketing agreement
which provides that, subject to certain limited exemptions, the new shares may
not be disposed of within 12 months following the closing date of the
subscription, which is expected to be 31 October 2007, other than through
Evolution Securities Limited, the Company's broker and nominated advisor, so as
to ensure an orderly market for the issued share capital of the Company. An
application will be made for the new Entelos shares to be admitted to trading on
AIM and admission is expected to become effective on 9 November 2007.

James Karis, President and CEO of Entelos stated: "We are pleased that Pfizer
has agreed to increase its holding in the Company. We plan to utilise the
proceeds of this investment to facilitate the Company's growth strategy."

For further information please contact:

Entelos, Inc.                                                                                       Tel: +1 650 572 5400
Alan Blazei, CFO
Jill Fujisaki, VP, Investor Relations

Evolution Securities                                                                            Tel +44 (0) 20 7071 4300
Tim Worlledge, Director
Bobbie Hilliam, Associate Director

Buchanan Communications                                                                         Tel +44 (0) 20 7466 5000
Lisa Baderoon
Mary-Jane Johnson

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver toxicity.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Entelos Regs Charts.